Here's who you could meet at BIO Partnering™ @ London Life Sciences Week

"Kerna Ventures is a London-based venture capital fund that invests in early-stage therapeutic companies. The fund's specialty focus is genetic medicine and advanced modalities but will consider all therapeutics companies on a case-by case basis. The fund can invest globally. At LLSW the Kerna team is seeking new investment opportunities and looking to network with other investors interested in the same areas."

Daniel Moore & Jack Byrne
Investment Lead
Kerna Ventures

"Trace Neuroscience is advancing TRCN-1023 in a global clinical program for ALS. Our antisense oligonucleotide is designed to restore UNC13A function, a genetically validated target relevant to about 97% of people with ALS, with the potential to reestablish neuronal communication disrupted by the disease. At LLSW, we're looking to connect with partners who share our urgency to expand genomic medicine across ALS and other neurodegenerative diseases."

Nick Mordwinkin, Pharm.D., Ph.D.
Chief Business Officer & Chief Strategy Officer
Trace Neuroscience

"Chugai Pharmaceutical is a research-driven biopharmaceutical company with proprietary drug discovery capabilities, particularly in antibody engineering and oral mid-sized molecules. At LLSW, we are looking to connect with innovative biotech companies and VCs with relevant portfolio companies, particularly those with technologies that could complement our drug discovery capabilities. We are also seeking later-stage therapeutic opportunities for the Japanese market and highly differentiated early-stage assets with global potential. We look forward to exploring flexible partnership opportunities built on compelling science and strong strategic fit."

Yasuhiro Kishi
Chugai Partnering
Chugai Pharmaceutical Co., Ltd.

"Bioqube Ventures is a global investment firm backing innovative therapeutics companies, with offices in Europe and the US. We invest across early stage and clinical stage, covering different therapeutic areas and modality types. The team is looking forward to connecting with late preclinical and clinical stage companies, as well as catching up pharma BD and research teams during LLSW.”

Alexander Demoulin
Principal
Bioqube Ventures

"At Taisho Pharmaceutical we invest in early-stage companies developing innovative solutions to address unmet medical needs and seek opportunities for strategic collaboration. We are particularly interested in differentiated therapies for autoimmune diseases, as well as innovative medical devices and digital therapeutics across a wide range of therapeutic areas. We look forward to connecting with life sciences founders from the UK and around the world during London Life Sciences Week to discuss potential investment and collaboration opportunities."

Maki Hirate
Manager, Investment, New Business Development
Taisho Pharmaceutical

"o2h ventures is looking to connect with other therapeutics investors, biotech founders, emerging companies and pharma partners advancing promising drug discovery programmes. Our portfolio of 60+ companies may offer opportunities for licensing, investment, or acquisition.

We’re also exploring co-discovery opportunities where our integrated drug discovery capabilities, strategic collaborations and AI-enabled platform can help advance programmes toward lead candidates. We’re open to flexible, capital-efficient models, including risk-sharing, sweat equity and IP-sharing, aligned with the long-term success of each programme."

Prashant Shah
Co-Founder
o2h Ventures

"We are attending London Life Sciences Week to meet fellow investors, strategic industry partners, and key stakeholders across the biotech sector. Our goal is to strengthen our international network, develop new syndication and collaboration opportunities, and exchange insights on the evolving life sciences landscape. We look forward to building relationships that can help accelerate innovation and growth across the industry to bring discoveries to lives."

Kevin Dalgaard, Ph.D.
Senior Principal
Lundbeckfonden BioCapital

“Events like Bio Partnering during London Life Sciences Week remind us that biotech is ultimately a people business. Great companies are born from the conversations, partnerships, and shared ambition that bring our ecosystem together.”

Zhizhong (Joel) Yao
Partner
Sofinnova Biovelocita

"I'm looking forward to reconnecting in person with our co-investors and comparing notes on where we're each seeing the most compelling opportunities. I'm also keen to build new relationships with business development leads across the pharma landscape, with an eye toward future partnering. Of course, I'm always glad to meet founders and management teams from emerging biotech companies who are building something worth backing."

Matt Martin
Partner
Pathway Bioventures